TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totaling 9,356 shares, a decrease of 47.7% from the September 15th total of 17,898 shares. Based on an average trading volume of 2,596 shares, the short-interest ratio is presently 3.6 days.
TriSalus Life Sciences Price Performance
Shares of NASDAQ:TLSIW opened at $0.98 on Wednesday. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $0.85. TriSalus Life Sciences has a 52 week low of $0.44 and a 52 week high of $1.85.
Institutional Investors Weigh In On TriSalus Life Sciences
An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp acquired a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 610,963 shares of the company’s stock, valued at approximately $2,780,000.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology company focused on developing and commercializing therapies and medical technologies for difficult-to-treat solid tumors, particularly liver and pancreatic cancers. The company combines interventional oncology, drug delivery and immunotherapy to address the tumor microenvironment and improve treatment delivery.
TriSalus’ technology platform includes Pressure-Enabled Drug Delivery (PEDD), a method designed to help administer therapies directly into tumors or their associated blood vessels.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
